重庆智翔金泰生物制药股份有限公司2025年第一次临时股东大会决议公告

Group 1 - The company held its first extraordinary general meeting of shareholders on November 18, 2025, at Chongqing Junhao Grand Hotel [2][10] - All resolutions presented at the meeting were approved, including the cancellation of the supervisory board and amendments to the company's articles of association [5][10] - The meeting was conducted in compliance with the Company Law and the company's articles of association, with both on-site and online voting methods utilized [2][8] Group 2 - The company appointed Liu Liwen as the employee representative director of the second board of directors following the extraordinary general meeting [10][11] - Liu Liwen's resignation from the board was due to internal governance structure adjustments, and he will continue to hold other positions within the company [11][12] - The company confirmed that the composition of the second board of directors remains unchanged after Liu Liwen's appointment [11][12] Group 3 - The company announced a third-quarter performance briefing scheduled for November 28, 2025, to enhance investor understanding of its operational performance and development strategy [13][16] - Investors can submit questions prior to the meeting through a designated website, and the company will address common concerns during the briefing [14][18] - Key personnel, including the chairman and financial director, will participate in the performance briefing [17]